Curis and Genentech in Hedgehog pathway deal for cancer
Tissue repair and regeneration company Curis has licensed Genentech rights to its preclinical small-molecule and antibody Hedgehog pathway inhibitors for the development of cancer therapeutics.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.